This may suggest the activated but reprogrammed BCR signaling in CD5+ DLBCL patients, and the role of CD5 expression in mitigating BCR signaling, and promoting tumor cell survival by previous studies [7-10]. Here, BCR is linked to diffuse large B-cell lymphoma.